Glooko has entered a new global partnership with insulin dosing algorithm company Hedia for the integration of the latter’s technology into its diabetes management platforms to better serve healthcare providers (HCPs) and diabetes patients.
To improve access for individuals with Type 1 and Type 2 diabetes requiring bolus insulin dosing advice, the partnership will offer an interoperable solution that combines connected care, digital therapeutic technologies and remote patient monitoring.
Hedia CEO Peter Lucas said: “We are thrilled to call Glooko, a company with such an extensive clinical network, our partner in digital health.”
Patients are currently using Glooko platforms to share their diabetes data with their HCPs.
The integration of the Hedia Diabetes Assistant will enable the users of Glooko’s diabetes management platforms to receive bolus insulin dosing advice.
It will eliminate the need to manually calculate required insulin doses.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The integrated solution can also be used in combination with connected insulin pens to enable HCPs to efficiently manage patients on multiple-daily injection (MDI) therapy.
The integration is anticipated to improve the capabilities of Glooko’s remote patient monitoring in addition to supporting virtual consultations for MDI patients.
Glooko CEO Russ Johannesson said: “The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps.
“This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”
The companies are planning the initial launch of the integrated solution in Europe between the fourth quarter of this year and the first quarter of next year.